Latest articles and price-sensitive announcements with AI sentiment classification.
This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look. The post Should I invest $10,000 in CSL shares before the end of May? appeared first on The Motley Fool Australia.
CSL Shares Dip To Start Week. Volume Slows Following Latest Sell-off thebull.com.au
Has the market become too pessimistic about Australia's biotech giant? The post CSL shares crash, but is a comeback looming? appeared first on The Motley Fool Australia.
Assessing CSL (ASX:CSL) Valuation After Interim CEO Review And Financial Update simplywall.st
CSL and Healius dragged the healthcare sector sharply lower this week, but EBR Systems and Blinklab still gave investors something ... Read More The post Scott Power: CSL bleeds in ‘shocking week’ for ASX healthcare stocks appeared first on Stockhead.
Scott Power: CSL bleeds in ‘shocking week’ for ASX healthcare stocks Stockhead
The safer choice may not be the one with the most upside. That is why this comparison is tricky. The post CSL shares vs CBA shares: Which is the better buy? appeared first on The Motley Fool Australia.
Highlights CSL’s dividend profile has become more noticeable following a sharp share price reset. The healthcare giant continues balancing growth ambitions with shareholder distributions. Market attention remains divided between earnings concerns and long-term healthcare demand. CSL returned to market focus after valuation weakness lifted its dividend profile while healthcare demand growth and operational recovery themes continued shaping sentiment toward the biotech giant. CSL Ltd (ASX...
Why CSL shares could be one of the best buys on the ASX right now The Motley Fool Australia
Here's what to expect over the next 12 months. The post Down 59%: Will CSL shares ever regain momentum? appeared first on The Motley Fool Australia.
Down 59%: Will CSL shares ever regain momentum? The Motley Fool Australia
Has the biotech giant switched from being a growth stock to an income stock now? Let's check. The post Is CSL now an ASX dividend stock to buy? appeared first on The Motley Fool Australia.
Is CSL now an ASX dividend stock to buy? The Motley Fool Australia
CSL (ASX:CSL) Down 44% YTD at Decade Lows: Buying Opportunity or Falling Knife? Stocks Down Under
‘True believer’ brokers split with market gloom as CSL shares slump AFR
Highlights CSL shares plunged after weaker guidance and major impairment announcements rattled market sentiment Healthcare stocks dragged the broader market lower as energy and mining sectors outperformed Investors are weighing inflation concerns, commodity strength, and global geopolitical risks CSL’s sharp decline weighed heavily on the healthcare sector while rising commodity prices supported mining and energy stocks across the australian stock market. Australian shares faced ...
Amid a renewed sell-off, healthcare analysts have pared their CSL valuations following yesterday's 'bloody' downgrade. ... Read More The post Health Check: Analysts deliver a harsh verdict on CSL appeared first on Stockhead.
The broker has been looking over the biotech giant's guidance downgrade. The post 'Blood on the Street': What is Bell Potter saying about the CSL share price crash? appeared first on The Motley Fool Australia.
Down 63%: Should you finally give up on CSL shares? The Motley Fool Australia
Highlights CSL flagged fresh impairment-related pressure across upcoming financial periods Revenue outlook reflects softer conditions in several healthcare segments Vaccine and plasma operations remain central to long-term business direction CSL outlined fresh impairment expectations alongside a softer outlook across key healthcare divisions, placing the healthcare giant under renewed market attention amid operational and sector-wide challenges. CSL Under Spotlight as Healthcare Giant R...
CSL served up a market shocker today, wiping billions off the ASX as investors piled out of healthcare and into ... Read More The post Closing Bell: CSL investors lose lunch (and arvo tea) as energy stocks bolster ASX appeared first on Stockhead.
Closing Bell: CSL investors lose lunch (and arvo tea) as energy stocks bolster ASX Stockhead
Highlights CSL faced renewed pressure after a fresh business update. Asset write-down concerns weighed heavily on sentiment. Investors continued tracking weakness across healthcare shares. CSL shares remained under pressure after the healthcare giant revised its outlook and highlighted further asset impairments, adding to concerns surrounding growth, operational performance, and long-term market confidence. CSL Faces Fresh Market Pressure as Concerns Mount Healthcare giant CSL Limited (...
CSL Shares Continue Lower as Update Adds Fuel To Bear Case: The Latest thebull.com.au
Highlights CSL continues to face intense market pressure amid changing healthcare sector conditions across Australian equities. Capital management activity remains active as the company navigates softer plasma collection conditions and margin compression. Broader healthcare sentiment across Australian equities has shifted alongside changing macroeconomic conditions. CSL remained under extensive market pressure as healthcare sector sentiment weakened across Australian equities amid chang...
CSL falls continue; ASIC probes DroneShield over stock sales The Australian
Highlights Healthcare sector pressure influenced broader Australian market sentiment. CSL remained under focus following operational and earnings-related developments. Geopolitical uncertainty added volatility across banking and mining sectors. Australian equities faced heightened volatility as CSL updates and geopolitical uncertainty weighed on healthcare, banking, and mining sectors. Australia’s equities market experienced heightened volatility as healthcare sector weakness and ...
Shares in Australian blood products giant CSL Limited (ASX: CSL) have crashed to a decade low after revealing US$5 billion ($6.9 billion) in additional non-cash impairments and a further downgrade to full-year earnings guidance, signalling the company's turnaround will take significantly longer than previously flagged. Shares in CSL hit an ...
Is CSL the ASX’s biggest ever blue chip disaster? How the model is broken Market Index
Lunch Wrap: CSL spooks the market as ASX slides Stockhead
The ASX was down on Monday as CSL blew a crater through healthcare sector, Trump rejected Iran’s peace proposal. ... Read More The post Lunch Wrap: CSL spooks the market as ASX slides appeared first on Stockhead.
Highlights Healthcare giant CSL remained in focus following major market activity linked with operational updates. Impairment-related developments and revised company targets influenced broader healthcare sector discussions. Defensive healthcare stocks continued drawing attention across the ASX 20. ASX healthcare sector remained in focus as CSL attracted market attention following operational updates linked with impairments and revised financial targets. Australia’s healthcare sec...
CSL shares crash after another profit warning rocks investor confidence. The post CSL shares suffer their biggest one-day crash ever! What just went wrong? appeared first on The Motley Fool Australia.
CSL (ASX:CSL) Cuts FY26 Guidance and Flags US$5bn Impairment as Interim CEO Resets the Story Stocks Down Under
CSL reveals lower FY26 earnings guidance and significant asset impairments. The post CSL cuts FY26 guidance, flags $5bn in impairments appeared first on The Motley Fool Australia.
Live: Health giant CSL wipes out decade of share price gains on profit warning Australian Broadcasting CorporationASX 200 Live Today - Monday, 11th May Market IndexASX 200 LIVE: ASX down as CSL dives to 11-year low on profit warnings; Metcash, Dyno Nobel soar on trading updates AFR
CSL Shares Drop to Decade Low as Oversold Conditions Fail to Stem Tide thebull.com.au
A Look At CSL (ASX:CSL) Valuation After Seqirus Demerger Plan CEO Exit And Ongoing Share Price Weakness simplywall.st
Highlights CSL, BHP and Rio Tinto remained active across major sectors. AI-linked ETF activity continued drawing market participation. Mining and data infrastructure themes supported market momentum. CSL, BHP, Rio Tinto, NextDC and AI-linked investment themes remained active as healthcare, mining and technology sectors shaped Australian market participation. Australia’s healthcare, mining, technology and infrastructure sectors continued drawing broad market attention as leading co...
Writing off CSL entirely might be premature - or is it? The post CSL shares hit a 9-year low, time to buy or stay away? appeared first on The Motley Fool Australia.
CSL shares hit a 9-year low, time to buy or stay away? The Motley Fool Australia
The experts weigh in as these healthcare and retail sector giants hit fresh lows. The post CSL, Wesfarmers, Endeavour shares crash to multi-year lows: Buy, hold, or sell? appeared first on The Motley Fool Australia.
CSL Shares Touch Nine-Year Lows as 50% Decline Tests Market Patience thebull.com.au
CSL and Wesfarmers among scores of ASX shares hitting fresh 52-week lows The Motley Fool Australia
New US-Iran missile attacks and an interest rate rise in Australia sent the market lower today. The post CSL and Wesfarmers among scores of ASX shares hitting fresh 52-week lows appeared first on The Motley Fool Australia.
Writing off CSL entirely may be premature. The post CSL shares halved, can analysts be right about a 100% rebound? appeared first on The Motley Fool Australia.
CSL shares halved, can analysts be right about a 100% rebound? The Motley Fool Australia
Highlights CSL draws attention after recent price softness Valuation gap raises fresh market debate Growth outlook tied to pipeline and margins The Australian healthcare sector often reflects broader sentiment across the [ASX 200], and recent movements in CSL Limited (CSL) have brought renewed attention to how the market reassesses established leaders. Known for its global presence in biotechnology and plasma therapies, CSL has experienced a period of subdued momentum, prompting closer examin...
Highlights Share price softness draws renewed attention to valuation Core business strength remains anchored in global healthcare demand Market debate intensifies over future earnings trajectory Recent weakness in CSL’s share price has triggered a reassessment of its valuation, with attention shifting toward fundamentals, growth drivers, and the broader outlook for healthcare innovation. Reassessing CSL After Recent Price Movements CSL (ASX:CSL) has returned to market conversation...
A Fresh Look At CSL (ASX:CSL) Valuation After Recent Share Price Weakness simplywall.st
Here's what the experts are tipping for the shares over the next 12 months. The post CSL, Resmed, Cochlear shares crash to multi-year low: Buy, sell or hold? appeared first on The Motley Fool Australia.
CSL Shares Fall to New Multi-Year Low After 50% Drop thebull.com.au
Motley Fool
Google News
ASX
Stockhead
Kalkine